{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:32:39Z","timestamp":1788211959448,"version":"build-2803163510"},"reference-count":30,"publisher":"Bioscientifica","issue":"4","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A cohort of radioiodine-refractory differentiated thyroid cancer patients (RAI-R DTC) in a tertiary center underwent therapeutic interventions according to disease progression rate and metastasis location. We evaluated the independent impact of local and\/or systemic treatments on final outcomes in 122 RAI-R DTC patients (44.3% men, age at diagnosis 51.98 \u00b1 15.8 years) who were followed up for 9.5 years (1.4\u201350). Patients were divided into two groups: those with only locoregional persistent disease: group 1, n = 27 (22.1%) and those with distant metastases: group 2, n = 95 (77.9%). Patients from group 1 underwent mainly local procedures. The final outcome was 4\/27 (14.8%) partial-response (PR) and 23\/27 (85.2%) stable disease (SD). Of group 2 patients, 10\/95 underwent active surveillance for micrometastatic disease, and the remaining received either only local treatments (40\/95) or TKIs \u00b1 local treatments (45\/95). The final outcome was PR in 7\/95 (7.4%), SD in 38 (40%) and progressive disease in 50 (52.6%). Concerning group 2 in Kaplan\u2013Meier analysis, local metastasis stabilization with local and\/or systemic therapy had a favorable effect on survival (P &amp;lt; 0.02). Those treated with TKIs + local procedures, despite having more aggressive tumors, achieved more frequently local stabilization and had a similar outcome compared to those treated with only TKIs (P = 0.007). For group 2, in Cox proportional hazard analysis during the follow-up period, younger age at diagnosis and maintenance of tumor differentiation are predictors of more favorable OS and cancer-specific survival. In conclusion, the implementation of local procedures in RAI-R DTC management stabilizes metastatic lesions and potentially enhances survival. Further studies are warranted to validate these findings.<\/jats:p>","DOI":"10.1530\/erc-24-0024","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T05:59:30Z","timestamp":1739858370000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":2,"title":["Local treatments and TKI efficacy in radioiodine refractory differentiated thyroid carcinoma patients: a single center experience"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1421-0653","authenticated-orcid":true,"given":"Katerina","family":"Saltiki","sequence":"first","affiliation":[{"name":"Endocrine Unit, Department of Clinical Therapeutics, National and Kapodistrian University 1 , ,","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-5885","authenticated-orcid":true,"given":"Olga","family":"Karapanou","sequence":"additional","affiliation":[{"name":"Endocrine Department, 401 General Military Hospital of Athens 2 , ,","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanella","family":"Kantreva","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Clinical Therapeutics, National and Kapodistrian University 1 , ,","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Michalaki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology-Department of Internal Medicine, School of Health Sciences, University of Patras 3 , ,","place":["Patras, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Koutsoukos","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Clinical Therapeutics, National and Kapodistrian University 1 , ,","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula A","family":"Paschou","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Clinical Therapeutics, National and Kapodistrian University 1 , ,","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alevizaki","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Clinical Therapeutics, National and Kapodistrian University 1 , ,","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"2026070905420892500_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/EJE-19-0763","article-title":"Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data","volume":"182","author":"Aydemirli","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"2026070905420892500_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.7150\/jca.22318","article-title":"Lenvatinib in advanced radioiodine-refractory thyroid cancer \u2013 a retrospective analysis of the Swiss lenvatinib named patient program","volume":"9","author":"Balmelli","year":"2018","journal-title":"J Cancer"},{"key":"2026070905420892500_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"2026070905420892500_bib4","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","article-title":"Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial","volume":"35","author":"Brose","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026070905420892500_bib5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s12020-020-02477-0","article-title":"Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival","volume":"72","author":"De Leo","year":"2021","journal-title":"Endocrine"},{"key":"2026070905420892500_bib6","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905420892500_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026070905420892500_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1210\/jc.2005-1322","article-title":"Survival and death causes in differentiated thyroid carcinoma","volume":"91","author":"Eustatia-Rutten","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905420892500_bib9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N Engl J Med"},{"key":"2026070905420892500_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12022-015-9410-7","article-title":"Unusual thyroid carcinoma metastases: a case series and literature review","volume":"27","author":"Farina","year":"2016","journal-title":"Endocr Pathol"},{"key":"2026070905420892500_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070905420892500_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur Thyroid J"},{"key":"2026070905420892500_bib13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1530\/ERC-18-0049","article-title":"Prolonged duration of response in lenvatinib responders with thyroid cancer","volume":"25","author":"Gianoukakis","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026070905420892500_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/847108","article-title":"Thyroid cancer: molecular aspects and new therapeutic strategies","volume":"2012","author":"Grande","year":"2012","journal-title":"J Thyroid Res"},{"key":"2026070905420892500_bib15","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac048","article-title":"Lenvatinib therapy for advanced thyroid cancer: real-life data on safety, efficacy, and some rare side effects","volume":"6","author":"Hamidi","year":"2022","journal-title":"J Endocr Soc"},{"key":"2026070905420892500_bib16","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00259-022-05697-w","article-title":"Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival","volume":"49","author":"Jannin","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070905420892500_bib17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12020-020-02290-9","article-title":"Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina","volume":"69","author":"Jerkovich","year":"2020","journal-title":"Endocrine"},{"key":"2026070905420892500_bib18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12020-024-03867-4","article-title":"Ten years' real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer","volume":"85","author":"Jerkovich","year":"2024","journal-title":"Endocrine"},{"key":"2026070905420892500_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/thy.2022.0054","article-title":"Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study","volume":"33","author":"Kim","year":"2023","journal-title":"Thyroid"},{"key":"2026070905420892500_bib20","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1089\/thy.2021.0091","article-title":"Real-World efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid"},{"key":"2026070905420892500_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","article-title":"Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy","volume":"118","author":"Locati","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026070905420892500_bib22","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1089\/thy.2011.0535","article-title":"The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland","volume":"22","author":"Nixon","year":"2012","journal-title":"Thyroid"},{"key":"2026070905420892500_bib23","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1089\/thy.2019.0246","article-title":"Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment: a Korean multicenter study","volume":"29","author":"Oh","year":"2019","journal-title":"Thyroid"},{"key":"2026070905420892500_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8834148","article-title":"Real-World data for lenvatinib in radioiodine-refractory differentiated thyroid cancer (RELEVANT): a retrospective multicentric analysis of clinical practice in Austria","volume":"2020","author":"Rendl","year":"2020","journal-title":"Int J Endocrinol"},{"key":"2026070905420892500_bib25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1210\/jc.2005-1534","article-title":"Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning","volume":"91","author":"Robbins","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905420892500_bib26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070905420892500_bib27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1089\/thy.2019.0476","article-title":"Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea","volume":"30","author":"Song","year":"2020","journal-title":"Thyroid"},{"key":"2026070905420892500_bib28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.atherosclerosis.2017.03.039","article-title":"Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: potential role of vascular endothelial dysfunction","volume":"260","author":"Sueta","year":"2017","journal-title":"Atherosclerosis"},{"key":"2026070905420892500_bib29","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-21-0111","article-title":"Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study","volume":"11","author":"Vallejo Casas","year":"2022","journal-title":"Eur Thyroid J"},{"key":"2026070905420892500_bib30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s12020-019-01991-0","article-title":"Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases","volume":"65","author":"Zunino","year":"2019","journal-title":"Endocrine"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/4\/ERC-24-0024.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/4\/ERC-24-0024.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0024\/144891\/erc-24-0024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0024\/144891\/erc-24-0024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:42:16Z","timestamp":1783590136000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/4\/e240024\/25896\/Local-treatments-and-TKI-efficacy-in-radioiodine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0024","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"article-number":"e240024"}}